Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)

Trial Profile

Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Afatinib (Primary) ; Docetaxel
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
    • 06 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top